[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
December 8, 2004

Stenting Small Coronary ArteriesWorks in Progress

Author Affiliations
 

Author Affiliation: Cardiovascular Diseases and Internal Medicine, Mayo Clinic and Foundation, Rochester, Minn.

JAMA. 2004;292(22):2777-2778. doi:10.1001/jama.292.22.2777

Interventional cardiology has a long and rich tradition of randomized clinical trials, the results of which have dramatically improved patient care. In the past few years, attention has particularly focused on drug-eluting stents, which have quickly become predicate devices (ie, against which new stents are compared). In the case of sirolimus-eluting stents, device approval was based in large measure on the 2 initial randomized clinical trials of RAVEL1 and SIRIUS.2 Based on the dramatic improvement in reducing restenosis with these devices demonstrated in these 2 trials, patients and physicians alike have embraced this new technology and physicians have used drug-eluting stents in subsets of patients for whom the data from trials were very limited. Early randomized trials of any device or drug typically target restricted “ideal” patient groups; this was certainly the case with the early drug-eluting stent trials. An important subset of patients that were not the focus of these early trials were those with clinically important stenoses of small coronary arteries.

First Page Preview View Large
First page PDF preview
First page PDF preview
×